Analyzing cell responses analyze (14 résultats)

Hardcover. Etat : Near Fine. 1402036221. Hardcover, from closed pharmaceutical company library. Lending record shows this book has never been borrowed. 313 pages, index, illustrated with charts, tables and diagrams. A critical assessment of all assays that have been used for the monitoring of antigen-specific immune responses. Emphasizes a global approach to the analysis of T cell mediated target/host interactions at the systemic and the peripheral level when such interactions are supposed to occur. Useful in the search of surrogate biomarkers predictive of treatment responsiveness and/or clinical outcome that are of interest to the biotechnology industry. Provides an overview of antigen-specific immune biology in human models of tumor and viral disease, discusses modulation of such responses through immune escape and presents cellular assays (cytoxicity, proliferation, cytokine production using ELISPOT, intracellular staining or cytometric assessment, detection of antigen-specific T cells with tetrameric HLA/epitope complexes or MHC-IG dimers, T cell receptor analysis, assessment of T cell receptor/HLA interactions using peptide/HLA-Green Fluorescent Protein complexes incorporation) and molecular assays including quantitative real-time PCR and gene profiling for evaluation of systemic and peripheral immune responses. Contents clean, tight and bright. Book.…

Etat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Etat : New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Etat : New.

Etat : New.

Etat : New. In English.

Etat : New.

Etat : As New. Unread book in perfect condition.

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.…

Paperback. Etat : Brand New. 325 pages. 9.25x6.10x0.77 inches. In Stock.

Hardcover. Etat : Brand New. 1st edition. 313 pages. 9.75x6.75x0.75 inches. In Stock.

Buch. Etat : Neu. Neuware - Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.…

Hardcover. Etat : Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Etat : As New. Unread book in perfect condition.